Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10915954 | Nuclear Medicine and Biology | 2015 | 7 Pages |
Abstract
The results of these studies supported the regulatory approval by Health Canada of 111In-BzDTPA-pertuzumab for a Phase I/II clinical trial of for imaging the response of patients with metastatic BC to treatment with trastuzumab combined with chemotherapy (PETRA trial; ClinicalTrials.gov identifier: NCT01805908).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Karen Lam, Conrad Chan, Susan J. Done, Mark N. Levine, Raymond M. Reilly,